

Joanne Kotsopoulos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2214661/publications.pdf>

Version: 2024-02-01

82
papers

2,169
citations

218677

26
h-index

254184

43
g-index

82
all docs

82
docs citations

82
times ranked

3251
citing authors

#	ARTICLE	IF	CITATIONS
1	Bilateral Oophorectomy and Breast Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	160
2	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	7.1	121
3	Changes in body weight and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2005, 7, R833-43.	5.0	103
4	Ten-year survival after epithelial ovarian cancer is not associated with <i>BRCA</i> mutation status. <i>Gynecologic Oncology</i> , 2016, 140, 42-47.	1.4	93
5	Infertility, treatment of infertility, and the risk of breast cancer among women with <i>BRCA1</i> and <i>BRCA2</i> mutations: a case-control study. <i>Cancer Causes and Control</i> , 2008, 19, 1111-1119.	1.8	87
6	Age at menarche and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Cancer Causes and Control</i> , 2005, 16, 667-674.	1.8	71
7	<i>BRCA</i> Mutations and Breast Cancer Prevention. <i>Cancers</i> , 2018, 10, 524.	3.7	71
8	The <i>CYP1A2</i> Genotype Modifies the Association Between Coffee Consumption and Breast Cancer Risk Among <i>BRCA1</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 912-916.	2.5	70
9	Timing of oral contraceptive use and the risk of breast cancer in <i>BRCA1</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 579-586.	2.5	68
10	Age-specific ovarian cancer risks among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	1.4	65
11	Breast cancer survival among young women: a review of the role of modifiable lifestyle factors. <i>Cancer Causes and Control</i> , 2016, 27, 459-472.	1.8	63
12	Hormone replacement therapy after menopause and risk of breast cancer in <i>BRCA1</i> mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	2.5	55
13	Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2017, 116, 964-971.	6.4	55
14	Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 585-593.	2.5	51
15	Age at first birth and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 221-228.	2.5	45
16	Hormone replacement therapy and the risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Gynecologic Oncology</i> , 2006, 100, 83-88.	1.4	43
17	Arsenic Exposure and Breast Cancer Risk: A Re-Evaluation of the Literature. <i>Nutrients</i> , 2020, 12, 3305.	4.1	42
18	The role of body size and physical activity on the risk of breast cancer in <i>BRCA</i> mutation carriers. <i>Cancer Causes and Control</i> , 2015, 26, 333-344.	1.8	40

#	ARTICLE	IF	CITATIONS
19	Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2019, 152, 145-150.	1.4	40
20	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	1.0	38
21	Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?. <i>Gynecologic Oncology</i> , 2017, 145, 346-351.	1.4	33
22	The Relationship Between Bilateral Oophorectomy and Plasma Hormone Levels in Postmenopausal Women. <i>Hormones and Cancer</i> , 2015, 6, 54-63.	4.9	32
23	Circulating plant miRNAs can regulate human gene expression in vitro. <i>Scientific Reports</i> , 2016, 6, 32773.	3.3	29
24	Revisiting breast cancer patients who previously tested negative for BRCA mutations using a 12-gene panel. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 135-142.	2.5	29
25	Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2016, 7, 86687-86694.	1.8	28
26	Can we prevent BRCA1-associated breast cancer by RANKL inhibition?. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 11-16.	2.5	27
27	Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. <i>JAMA Network Open</i> , 2022, 5, e2141633.	5.9	27
28	Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. <i>Cancer Causes and Control</i> , 2012, 23, 1065-1074.	1.8	26
29	Height, weight, BMI and ovarian cancer survival. <i>Gynecologic Oncology</i> , 2012, 127, 83-87.	1.4	25
30	Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 561-571.	2.5	25
31	Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. <i>Cancer Causes and Control</i> , 2010, 21, 679-687.	1.8	23
32	Folate and breast cancer: what about high-risk women?. <i>Cancer Causes and Control</i> , 2012, 23, 1405-1420.	1.8	23
33	Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 671-677.	4.7	23
34	Telomere Length and Mortality Following a Diagnosis of Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2603-2606.	2.5	21
35	Frequency of germline PALB2 mutations among women with epithelial ovarian cancer. <i>Familial Cancer</i> , 2017, 16, 29-34.	1.9	21
36	The association between smoking and cancer incidence in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2018, 142, 2263-2272.	5.1	20

#	ARTICLE	IF	CITATIONS
37	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. <i>Hereditary Cancer in Clinical Practice</i> , 2011, 9, 10.	1.5	19
38	Changes in Bone Mineral Density After Prophylactic Bilateral Salpingo-Oophorectomy in Carriers of a <i>BRCA</i> Mutation. <i>JAMA Network Open</i> , 2019, 2, e198420.	5.9	18
39	Folic acid supplement use and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 741-748.	2.5	17
40	Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target?. <i>International Journal of Cancer</i> , 2020, 147, 1245-1251.	5.1	17
41	Platelet Count and Survival after Cancer. <i>Cancers</i> , 2022, 14, 549.	3.7	17
42	Menopausal hormones: definitive evidence for breast cancer. <i>Lancet, The</i> , 2019, 394, 1116-1118.	13.7	15
43	A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy. <i>Gynecologic Oncology</i> , 2019, 155, 270-274.	1.4	15
44	Risk Factors for Premenopausal Breast Cancer in Bangladesh. <i>International Journal of Breast Cancer</i> , 2015, 2015, 1-7.	1.2	14
45	Serum Selenium Level Predicts 10-Year Survival after Breast Cancer. <i>Nutrients</i> , 2021, 13, 953.	4.1	14
46	Uninterrupted Sedentary Behavior Downregulates <i>BRCA1</i> Gene Expression. <i>Cancer Prevention Research</i> , 2016, 9, 83-88.	1.5	13
47	Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 435-441.	2.5	12
48	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	2.5	12
49	Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Epidemiology</i> , 2018, 47, 987-997.	1.9	11
50	Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study. <i>British Journal of Cancer</i> , 2018, 119, 1421-1427.	6.4	11
51	Iron intake, oxidative stress-related genes and breast cancer risk. <i>International Journal of Cancer</i> , 2020, 147, 1354-1373.	5.1	11
52	Prospective study of high-risk, BRCA1/2-mutation negative women: the "negative study"™. <i>BMC Cancer</i> , 2014, 14, 221.	2.6	10
53	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	2.5	10
54	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	1.4	10

#	ARTICLE	IF	CITATIONS
55	Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific. <i>Breast Cancer Research</i> , 2016, 18, 87.	5.0	9
56	The impacts of neoadjuvant chemotherapy and of cytoreductive surgery on 10-year survival from advanced ovarian cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 417-423.	2.3	9
57	The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada. <i>Cancers</i> , 2021, 13, 1894.	3.7	8
58	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. <i>Menopause</i> , 2020, 27, 1396-1402.	2.0	8
59	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2022, 164, 514-521.	1.4	8
60	Age-specific risks of incident, contralateral and ipsilateral breast cancer among 1776 Polish BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 769-774.	2.5	7
61	Premenopausal Plasma Osteoprotegerin and Breast Cancer Risk: A Case-Control Analysis Nested within the Nurses' Health Study II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1264-1270.	2.5	7
62	The effect of oral 3,3'-diindolylmethane supplementation on the 2:16-OHE ratio in BRCA1 mutation carriers. <i>Familial Cancer</i> , 2015, 14, 281-286.	1.9	6
63	Serum osteoprotegerin levels and mammographic density among high-risk women. <i>Cancer Causes and Control</i> , 2018, 29, 507-517.	1.8	6
64	Blood Arsenic Levels as a Marker of Breast Cancer Risk among BRCA1 Carriers. <i>Cancers</i> , 2021, 13, 3345.	3.7	6
65	Method of Cooking and Risk of Breast Cancer in the Philippines. <i>Cancer Causes and Control</i> , 2006, 17, 341-348.	1.8	5
66	Predictors of mammographic density among women with a strong family history of breast cancer. <i>BMC Cancer</i> , 2019, 19, 631.	2.6	5
67	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , 2020, 27, 156-161.	2.0	5
68	Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 515-523.	2.5	5
69	Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Oncotarget</i> , 2019, 10, 2475-2483.	1.8	5
70	Ovarian cancer survival by tumor dominance, a surrogate for site of origin. <i>Cancer Causes and Control</i> , 2015, 26, 601-608.	1.8	4
71	Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 199-200.	2.4	4
72	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 825-830.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Delineating the role of osteoprotegerin as a marker of breast cancer risk among women with a BRCA1 mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2022, 20, 14.	1.5	4
74	A BRCA1 Mutation Is Not Associated with Increased Indicators of Oxidative Stress. <i>Clinical Breast Cancer</i> , 2008, 8, 506-510.	2.4	3
75	Response. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	3
76	Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital. <i>Familial Cancer</i> , 2021, 20, 103-110.	1.9	3
77	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	2.5	3
78	Tubal histopathological abnormalities in <i>BRCA1/2</i> mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 41-47.	2.5	2
79	An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool. <i>Cancer</i> , 2021, 127, 3183-3193.	4.1	1
80	Abstract 857: Evaluating the relationship between arsenic exposure and cancer risk in Canada. , 2021, , .		0
81	Oral Contraceptives and BRCA Cancer: A Balancing Act. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	0
82	Abstract 5942: Vitamin D, calcium supplement use and the risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: A case-control study. <i>Cancer Research</i> , 2022, 82, 5942-5942.	0.9	0